Abstract: A touch display panel and a touch display apparatus, including: a substrate; a shielding layer disposed on one side of the substrate and including a plurality of shielding units arranged in array; a touch function layer disposed on a side of the shielding layer facing away from the substrate and including a plurality of touch electrodes arranged in array; and a plurality of electrode wires in one-to-one correspondence to and electrically connected to the plurality of touch electrodes. The plurality of electrode wires include at least one first-type electrode wire including a first lead wire and a second lead wire electrically connected to the first lead wire. The first lead wire is in the same layer as the touch function layer. The second lead wire is in the same layer as the shielding layer and spaced apart and insulated from the shielding units.

Abstract: The present disclosure is concerned with substituted N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds, and methods of treating and/or preventing neurodegenerative or neurocognitive disorders including, but not limited to, Alzheimer's disease, cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy (CADASIL), Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS/Lou Gehrig's disease), Multiple Sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy, familial spastic paraparesis, Machado Joseph disease, Friedreich's ataxia, Lewy body disease, and dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia, mixed dementia, dementia induced by Alzheimer's disease or Parkinson's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A display panel and a display apparatus. The display panel includes: a light-emitting device layer including a base plate and a light-emitting layer arranged in stack; a touch control layer including touch control electrodes and a planarization layer covering the touch control electrodes; a buffer layer arranged at a side of the planarization layer away from the light-emitting device layer; an optical film layer arranged at a side of the buffer layer away from the touch control layer and including a plurality of black matrices and a plurality of light filtering units arranged in the same layer as the black matrices; a material of the buffer layer and a material of the planarization layer are immiscible, and an orthographic projection of the buffer layer on the base plate covers an orthographic projection of the light filtering units on the base plate.

Abstract: A touch display panel and a touch display apparatus, including: a substrate; a shielding layer disposed on one side of the substrate and including a plurality of shielding units arranged in array; a touch function layer disposed on a side of the shielding layer facing away from the substrate and including a plurality of touch electrodes arranged in array; and a plurality of electrode wires in one-to-one correspondence to and electrically connected to the plurality of touch electrodes. The plurality of electrode wires include at least one first-type electrode wire including a first lead wire and a second lead wire electrically connected to the first lead wire. The first lead wire is in the same layer as the touch function layer. The second lead wire is in the same layer as the shielding layer and spaced apart and insulated from the shielding units.

Abstract: A photosensitive circuit structure and an optical device, where the photosensitive circuit structure includes a photosensitive unit, a signal amplification unit and a control unit; the photosensitive unit includes a photodiode and a reset transistor, the signal amplification unit includes an amplification transistor, and the control unit includes a control transistor; an input terminal, an output terminal and a control terminal of the reset transistor are electrically connected to a power supply terminal, a control terminal of the amplification transistor and a reset signal terminal, respectively; an input terminal and output terminal of the amplification transistor are electrically connected to the power supply terminal and an input terminal of the control transistor respectively, and a control terminal of the control transistor is connected to a signal control terminal.

Abstract: A strong FXR small-molecule agonist, and a preparation method therefor and use thereof, the structure of the agonist being represented by formula (I), are provided. In the formula, each substituent is as defined in the description and the claims. The compound provided has the advantages of high FXR agonist activity, simple synthesis, easily available raw materials and the like, and can be used for preparing medicines for treating FXR related diseases.

Abstract: Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.

Abstract: A quantitative statistical characterization method of micron-level second phase in aluminum alloy based on deep learning is disclosed. The method includes obtaining a feature database of the standard sample, training the feature database by the image segmentation network U-Net based on deep learning to obtain a U-Net segmentation model, selecting the corresponding parameters of the optimal precision and establishing a U-Net target model; clipping the aluminum alloy image to be detected and inputting the clipped images into the U-net target model, obtaining the size, area and position information of the second phase through the connected region algorithm, carrying out statistical distribution of the data set combined with the mathematical statistical method, and restoring the position information to the surface of the aluminum alloy to be tested to obtain the full-field quantitative statistical distribution and visualization results.

Abstract: A self-adaptive heavy-duty gear transmission walking device includes a guide track. A carrying seat is slidably installed on the guide track. A loading platform is arranged on the carrying seat, and matching frames are arranged at the bottom of the carrying seat and positioned opposite from each other. A first driving mechanism, a walking mechanism, a first support bracket, a stop mechanism, and a second support bracket are arranged on the carrying seat. A vertical support mechanism and a horizontal support mechanism are arranged in the matching frame. The first driving mechanism is connected to one end of the walking mechanism. The walking mechanism penetrates through the carrying seat and is magnetically connected to the guide track. The other end of the walking mechanism is connected to a first transmission shaft. The first transmission shaft penetrates through the first support bracket and is fixedly installed with a brake disc.

Abstract: An image acquisition method. N images of an object to be shot are acquired. The N images are shot by N shooting devices. Shooting fields of view of the N shooting devices are different from each other. The N images are in one-to-one correspondence with the N shooting devices. Feature extraction is performed on the N images to obtain M features of the N images. M is an integer multiple of N. The M features include M/N types of features.

Abstract: The present disclosure is concerned with substituted N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds, and methods of treating and/or preventing neurodegenerative or neurocognitive disorders including, but not limited to, Alzheimer's disease, cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy (CADASIL), Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS/Lou Gehrig's disease), Multiple Sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy, familial spastic paraparesis, Machado Joseph disease, Friedreich's ataxia, Lewy body disease, and dementia (e.g., vascular dementia, Lewy body dementia, frontotemporal dementia, mixed dementia, dementia induced by Alzheimer's disease or Parkinson's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Provided are a humanized anti-A? monoclonal antibody and use thereof. The humanized anti-A? monoclonal antibody provided can inhibit the polymerization of A? monomers, protect nerve cells from the toxicity of A?, and have a certain effect on improving the cognitive learning and memory ability of Alzheimer's dementia model mice, and can be used for the treatment and diagnosis of diseases and disorders related to amyloidosis, such as Alzheimer's disease.

Abstract: An FXR small molecule agonist and a preparation method therefor and a use thereof, having a structure as shown in formula (I). The compound represented by formula (I) has FXR agonistic activity and is capable of preparing drugs for treatment of FXR-related diseases.

Abstract: The present disclosure relates to the technical field of medical equipment and discloses an anastomotic/occlusion reinforcing and repairing composite member which includes a reinforcing and repairing portion, a protection portion and a connecting thread, wherein two ends of the reinforcing and repairing portion are detachably connected by the connecting thread; and the protection portion penetrates into a space enclosed by the two ends of the reinforcing and repairing portion. The present disclosure also provides a preparation and application method of the anastomotic/occlusion reinforcing and repairing composite member.

Abstract: The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of neurological diseases/disorders involving Na+-K+-20?-cotransporters (NKCCs), such as stroke, traumatic brain injury (TBI), spinal cord injury (SCI), peripheral nerve injury (PNI), brain edema, or glioma, and particularly for use in the treatment or prevention of stroke. The invention likewise relates to a method of treating or preventing a neurological disease or disorder involving an NKCC, such as stroke, TBI, SCI, PNI, brain edema, or glioma, the method comprising administering a compound of formula (I) to a subject in need thereof.

Abstract: The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.

Abstract: The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.